rs10733113 GG | rs10733113 AG | rs10733113 AA | p value (Fisher or Kruskal–Wallis) | |
---|---|---|---|---|
Gender | ||||
Male (n = 369) Female (n = 321) | 276 (53.5%) 240 (46.5%) | 10 (71.4%) 4 (28.6%) | 83 (51.9%) 77 (48.1%) | 0.392 |
Age at diagnosis [years] | ||||
Median, q25–q75, Min–max | 27.7, 19.8–38.7, 2.9–79.6 | 38.0, 27.1–40.8, 19.5–63.2 | 29.2, 19.7–36.7, 3.4–69.4 | 0.099 |
Disease duration [years] | ||||
Median, q25–q75, Min–max | 11.1, 6.7–18.4, 0.2–49.5 | 10.7, 7.8–17.8, 2.9–26.3 | 11.7, 7.3–18.8, 0.5–40.1 | 0.619 |
Complications* | ||||
No (n = 286) Yes (n = 404) | 225 (43.6%) 291 (56.4%) | 6 (42.9%) 8 (57.1%) | 55 (34.4%) 105 (65.6%) | 0.122 |
MTWAI–maximal value throughout follow-up | ||||
Median, q25–q75, Min–max | 4, 2–8.5, 0–19 | 7.5, 3–9, 0–13 | 5, 2–9, 0–17 | 0.704 |
Reported flare* No (n = 284) Yes (n = 406) | 213 (41.3%) 303 (58.7%) | 7 (50.0%) 7 (50.0%) | 64 (40.0%) 96 (60.0%) | 0.753 |
Flare possibly or highly related to (focus on yes): | ||||
NSAIDs Antibiotics GI tract infection Other infection Treatment decr. / disc Other medication | 19 (6.3%) 6 (2.0%) 51 (16.8%) 29 (9.6%) 74 (24.4%) 9 (3.0%) | 0 (0%) 1 (14.3%) 1 (14.3%) 0 (0%) 2 (28.6%) 0 (0%) | 4 (4.2%) 1 (1.0%) 22 (22.9%) 10 (10.4%) 22 (22.9%) 5 (5.2%) | 0.746 0.150 0.347 0.924 0.864 0.484 |
Flare management (focus on the yes): | ||||
Hospitalization Ambulatory Surgery Drug therapy | 39 (12.9%) 89 (29.4%) 16 (5.3%) 271 (89.4%) | 0 (0%) 1 (14.3%) 0 (0%) 7 (100%) | 7 (7.3%) 14 (14.6%) 3 (3.1%) 90 (93.8%) | 0.278 0.008 0.702 0.367 |
Focus on the hospitalizations: | ||||
Total days of hosp. Median, q25–q75, Min–max | 4, 0–16, 0–90 | – | 0, 0–3, 0–12 | 0.063 |